GlassScriptPhysician profile
Krystal Ann Wright
NPI 1447804497
$1,410.86
in general payments reported to CMS, 2019-2025
21 companies · $577 in 2025
The $577 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $56.09 · 2022: $29.46 · 2023: $438 · 2024: $311 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,325.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $280.43 | 2023-2025 | Accrufer |
| Lilly USA, LLC | $263.32 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $112.96 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $111.81 | 2023-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $101.55 | 2024-2025 | |
| Boston Scientific Corporation | $94.73 | 2023-2024 | Watchman Flx |
| Glaxosmithkline, LLC. | $73.66 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Organon LLC | $61.80 | 2022-2025 | Nexplanon |
| Pfizer INC. | $61.54 | 2023-2025 | |
| Axsome Therapeutics, INC. | $33.86 | 2025 | Auvelity |
| Alnylam Pharmaceuticals INC. | $32.96 | 2024 | Givlaari |
| Astrazeneca Pharmaceuticals LP | $30.49 | 2023-2025 | Breztri, Airsupra |
| Azurity Pharmaceuticals, INC. | $23.61 | 2025 | Azmiro |
| Abbott Laboratories | $21.80 | 2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $18.74 | 2023 | Camzyos |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $16.42 | 2021 | |
| Astellas Pharma US INC | $15.92 | 2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.59 | 2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $14.14 | 2021 | |
| Eisai INC. | $13.03 | 2021 | |
| Clarus Therapeutics INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krystal Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.